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Abstract
Background: Numerous studies show that high circulating level of glucocorticosteroids is a biochemical characteristic of
Alzheimer’s disease (AD). These stress hormones can increase the amount of AD-like pathology in animal models of the disease.
Since they also up-regulate the 5-Lipoxygenase (5-LO), an enzyme which modulates amyloid beta (Ab) formation, in the present
paper we tested the hypothesis that this enzymatic pathway is involved in the glucocorticoid-induced pro-amyloidotic effect.
Methodology/Principal Findings: Incubation of neuronal cells with dexamethasone resulted in a significant increase in 5-
LO activity and Ab formation. By contrast, pharmacological inhibition of 5-LO prevented the dexamethasone-dependent
increase in Ab levels. Mouse embryonic fibroblasts responded with a significant increase in Ab formation after
dexamethasone challenge. However, this effect was abolished when dexamethasone was incubated with fibroblasts
genetically deficient for 5-LO. No difference in the glucocorticoid receptor levels was observed between the two groups.
Finally, treatment of wild type mice with dexamethasone resulted in a significant increase in endogenous brain Ab levels,
which was prevented in mice genetically lacking 5-LO.
Conclusions: These findings suggest that 5-LO plays a functional role in the glucocorticoid-induced brain AD-like amyloid
pathology.
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Introduction
Alzheimer’s disease (AD) is the most common form of
neurodegenerative disease with dementia in the elderly, affecting
approximately 6–8% all persons aged .65 years [1]. While only a
minority of AD cases is caused by missense mutations in genes for
either the Ab precursor protein (APP) or Presenilin-1 and -2, the
cause of sporadic AD remains unclear, and a combination of
environmental and genetic factors with epigenetic events has been
implicated [2]. Psychosocial stress has been suggested to be one
important environmental factor that can influence AD age of onset
and/or development [3]. Several clinical studies have linked
dysregulation of stress hormone levels, such as glucocorticoids, with
AD pathogenesis. Plasma cortisol levels are increased in subjects
withmild cognitive impairment and in AD patients [4–6]. Recently,
it has been demonstrated that chronic stress and glucocorticoids
promote amyloid beta (Ab) deposition and tau accumulation in
transgenic mouse models of AD [7,8]. Among the different
biological actions, dexamethasone is known to increase the
expression levels of the 5-Lipoxygenase (5-LO), an enzyme widely
expressed in the central nervous system (CNS) where it localizes
mainly in neuronal cells [9]. Previous studies have reported that 5-
LO immunoreactivity is increased in hippocampi of AD patients,
and that itsproteinlevelsarehigher incortexandhippocampus, but
not cerebellum, of AD brains when compared with healthy controls
[10,11]. Further, genetic absence of 5-LO results in a significant
reduction of brain Ab levels and deposition in a transgenic AD
mouse model, suggesting that this enzymatic pathway plays a
functional role in modulating the amyloidotic phenotype of this
model [11]. In the presentstudy, we sought to determine whether 5-
LO was involved in the glucocorticoid-dependent Ab elevation. To
this end, we investigated the effect of dexamethasone on Ab
formation and metabolism in the presence and in the absence of 5-
LO enzymatic activity in vitro and in vivo. Here we confirm that
glucocorticoid challenge enhances the synthesis of Ab, and report
the novel finding that pharmacological blockade or genetic absence
of 5-LO prevents this biological effect. Our findings underscore a
new mechanism by which psychological stress affects AD-like
amyloid pathology and suggest that 5-LO could be a therapeutic
target in individuals where stress management or pharmacological
reduction of glucocorticoids approaches are not applicable.
Materials and Methods
Cell lines, cell culture and treatment
Neuro-2 A neuroblastoma (N2A) cells stably expressing human
APP carrying the K670 N, M671L Swedish mutation (APPswe)
were grown in Dulbecco’s modified Eagle medium supplemented
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Herdon, VA, USA) and 400 mg/mL G418 (Invitrogen, Carlsbad,
CA,USA), at 37uC in the presence of 5% CO2. HEK293-C99 cells
stably transfected with human C-terminal fragment C99 of human
APP containing Ab sequence were kindly provided by Dr. Robert
W. Doms (University of Pennsylvania, Philadelphia, USA) and
kept in culture as previously described [11]. For each experiment,
equal numbers of cells were plated in six-well plates, 24 hr later
media were removed and fresh media containing either dexa-
methasone (1 mM stock solution dissolved in H2O; cat. # D2915.
Sigma-Aldrich, St. Louis, MO) or vehicle were added. After an
overnight incubation, supernatants were collected for biochemistry
assays, and cell pellets harvested for biochemical analyses.
Mouse Embryonic Fibroblasts isolation
Mouse embryonic fibroblasts (MEFs) were obtained as previ-
ously described [11]. Briefly, pregnant female mice were sacrificed
12–13 days after observing vaginal plugs. Uterine horns were
dissected out, briefly rinsed in 70% ethanol and placed into a
sterile Petri dish containing phosphate buffered saline (PBS)
without bivalent cations. Each embryo was isolated and separated
from its placenta and surrounding membranes. The head, liver
and kidneys were removed and used for genotyping, and a cell
suspension of the remaining tissue was prepared by trituration in
1 ml trypsin-EDTA. Following gentle shaking at 37uC for 15 min
with 100 Kunitz units/mL of DNAse, the resulting cell suspensions
were incubated on ice for additional 15 min, then subjected to low
speed centrifugation (500 g) for 5 min. The resulting cell pellet was
plated into a 10 cm dish with pre-warmed MEF medium (DMEM
with high glucose, 10% fetal bovine serum, L-glutamine
(200 mM), and penicillin/streptomycin). The culture medium
was replaced with fresh DMEM after 24 h. After 2–3 passages,
MEFs were genotyped again to avoid possible errors in initial
genotyping due to maternal tissue contamination. APP x 5LO
+/+
and APP x 5LO
2/2 MEFs were always used for the experiments
described in the present paper.
Mice and treatments
All experiments were performed in accordance with animal
protocols approved by the Institutional Animal Care and Usage
Committee, and the U.S. National Institute of Health guidelines
(approval ID 3311). All mice used in the present study were
females. Twelve-month-old 5-LO
2/2 mice and wild type (WT)
littermates were administered with an intra-peritoneal injection of
either dexamethasone (dissolved in PBS at 1 mg/ml) or PBS alone
for 7 days. Dexamethasone was administered at 1 mg/kg body
weight or PBS vehicle. 24 h after the final injection, animals were
killed following procedures recommended by Panel or Euthanasia
of the American Veterinarian Medical Association. Brains were
removed after perfusion and immediately stored at 280uC for
biochemical analyses.
Biochemical analyses
All of the biochemical analyses were always performed in
triplicate and in a coded fashion.
Ab sandwich ELISA assay
Aliquots of brain samples were homogenized and extracted in
0.2% diethylamine (DEA)/50 mM NaCl at 1:10 W/v. Brain
homogenates were centrifuged for 1 hr at 100,0006ga t4 uC, and
supernatants were neutralized to pH 8.0 with 1:10 v/v of 0.5 Tris-
HCl/pH 6.8. Protein concentration in DEA extracts was
determined using the BCA Protein Assay kit (Pierce, Rockford,
IL). The Ab1-40 and 1-42 levels in the supernatants and in mouse
brain homogenates were determined using specific sandwich
ELISA kits as previously described, and following the manufac-
turer’s instructions [11,12] (Wako Chemicals, Japan).
Leukotriene B4 ELISA assay
Leukotriene B4 levels were assayed in supernatants and brain
homogenates by a specific and sensitive immunoassay according to
the manufacturer’s recommendation (Assay Designs; Ann Arbor,
MI, USA), and as previously described [13].
Western blot analyses
Cells were washed with PBS and lysed in RIPA buffer
(50 nmol/L Tris-HCL, 150 mmol/L NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, 2 mmol/L EDTA, 0,1% sodium
dodecyl sulfate) in the presence of an EDTA-free protease
inhibitor cocktail tablet (Roche Applied Science). Cell lysates
were sonicated and centrifuged at 14,000 g for 20 min at 4uC.
Aliquots of brain homogenates and cell lysates were assayed for
protein concentration by a BCA Protein Assay Kit. Equal amount
of protein from cell lysates or brain extracts (30 mg) were
electrophoresed on 3–8 % Tris-acetate gels and 10% Bis-Tris
gels, according to the molecular weight of the target molecule, and
then transferred on nitrocellulose membranes (Bio-Rad, Rich-
mond, CA, USA). They were blocked with Odyssey blocking
buffer for 1 h; and then incubated with primary antibodies
overnight at 4uC, as previously described [11–13]. After three
washings with T-TBS, incubation with IRDye secondary antibod-
ies (LI-COR Bioscience, NE, USA) were performed at 22uC for
1 h. The membranes were developed using infrared fluorescence
detection on the Odyssey and Aerius infrared imaging systems (LI-
COR Bioscience, USA). Antibodies and dilutions used for western
blot analysis were as follows: anti-APP N-terminal raised against
amino acids 66–81 for total APP (22C11; 1:1500; Chemicon
Inter., USA), anti-BACE1 (1;200; IBL America), anti-ADAM-10
(1: 500 dilution; Chemicon), anti-PS1 (1: 200; Cell Signaling,
USA), anti-nicastrin (1: 200; Cell Signaling), anti-PEN2 (1: 200;
Invitrogen, USA), anti-APH 1 (1: 200; Millipore, USA); anti-5LO
(clone 33;1:500; BD Bioscience), anti-b actin (1;4000, Santa Cruz
Biotechnology), anti-Glucocorticoid Receptor (1:500 Pierce Bio-
technology). IRDye infrared secondary antibodies were from LI-
COR Bioscience.
Immunofluorescence microscopy
Cell immunostaining was carried out as previously described
[12]. Briefly, N2A-APPswe cells were plated on glass cover slips
and the following day fixed in 4% paraformaldehyde in PBS for
15 min at 22uC. After rinsing several times with PBS, cells were
incubated in a blocking solution (5% normal serum / 0.4 % TX-
100) for 1 h at 22uC and then with the primary antibody against 5-
LO (1:500; BD Bioscience) overnight at 4uC. After several
washings with PBS, cells were incubated for 1 h with a secondary
Alexa546- conjugated antibody (1:800; Invitrogen). Cover slips
were mounted using VECTASHIELD mounting medium (Vector
Laboratories, Burlingame, CA) and analyzed with an Olympus
BX60 fluorescent microscope (Olympus, Center Valley, PA).
Excitation at 405 nm for 49,69-diamidino-2-phenylindole and 543
for Alexa546 was generated by diode and He-Ne ion lasers,
respectively. Fluorescence emission was collected at 425–475 nm
for 49, 6-diamidino-2-phenylindole and 555–656 nm for
Alexa546. Olympus Fluo BView 1.3 (Center Valley, PA, USA)
was used for image acquisition. Control cover slips were processed
as described above except that no primary antibody was added to
the solution.
5-Lipoxygenase, Corticosteroids and Amyloid Beta
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15163Statistical analysis
Data are presented as the mean 6 S.E.M. For each experi-
mental setting, data are expressed as percentage of the control
value of that specific experiment. Each control was arbitrarily set
at 100%. The percentage values obtained from different experi-
ments were then averaged and plotted as percentage of control. At
least three independent experiments were always performed in
each condition. An effect of treatment was defined as significant if
p,0.05 by analysis of variance (ANOVA), and subsequently by
student unpaired two-tailed t-test.
Figure 1. Immunocytochemical localization of 5-LO in N2A-APPswe cells. Cells were plated on glass cover slips, fixed in 4%
paraformaldehyde, then blocked with serum, incubated with a primary antibody against 5-LO. (a) 5-LO immunofluorescence, (b) DAPI staining, (c)
overlap of the two images. (magnification 640).
doi:10.1371/journal.pone.0015163.g001
Figure 2. Dexamethasone increases Ab formation in neuronal cells. N2A-APPswe cells were incubated with Dexamethasone (closed bars)
(10 mM) or vehicle (open bars) and conditioned media collected and assayed for (A) Ab 1–40 (B) Ab1-42 levels (n=6 per condition, *p,0.001), and (C)
LTB4 (*p,0.05). D. Representative immunoblots of cell lysates probed with antibodies against APP, 5-LO, and glucocorticoid receptor (GR) in control
and after dexamethasone treatment. Values represent mean 6 SEM.
doi:10.1371/journal.pone.0015163.g002
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Dexamethasone increases Ab formation in vitro via a 5-
LO-dependent manner
First, by using immunofluorescence microscopy we investigated
theexpression levels of 5-LO in the neuronalcells, N2A, whichwill be
used in our paper. As shown in Figure 1, we found that these cells
express high levels of this protein with the most intense positive
immunoreaction having a diffuse pattern and mainly localized in the
cytosol. Next, we challenged the N2A cells with dexamethasone
(10 mM) or vehicle, and observed the effect on Ab formation and 5-
LO activation. Compared with vehicle, dexamethasone induced a
significant increase in Ab 1–40 and 1–42 levels (Fig. 2A,B), which was
associated with a significant elevation in the production of leukotriene
B4 (LTB4), the major metabolic product of 5-LO activation (Fig. 2C).
Under this experimental conditions steady state expression levels of 5-
LO and GR receptor were unchanged (Fig. 2D).
Since we observed that dexamethasone incubation resulted in 5-
LO activation, as demonstrated by the increase in LTB4
formation, next we tested the hypothesis of whether pharmaco-
logical blockade of 5-LO will modulate the dexamethasone-
dependent increase of Ab formation. To this end, we used two
different pharmacological approaches: a selective and direct 5-LO
inhibitor (i.e., AA-861) [14], and a specific blocker of the 5-LO
activating protein (i.e., MK-591), also known as FLAP, which is
necessary for a full 5-LO activity [14]. At the concentration used
AA-861 significantly reduced LTB4 formation (control: 9667;
AA-861 1 mM: 5562; AA-861 5 mM: 2761.5; AA-861 10 mM:
8.661.5 pg/ml). A similar effect was observed in samples treated
with MK-591 (control: 9965.4; MK-591 5 mM: 5463.3; MK-591
10 mM: 2362.7; MK-591 25 mM: 7.3661.8 pg/ml).
In both cases, the drugs dose-dependently prevented the
dexamethasone-dependent effect on Ab 1–40 and 1–42 formation
(Fig. 3A–D). This effect was independent from any influence on
the steady state levels of APP or 5-LO in the same cells (Fig. 3E,F).
Effect of dexamethasone on Ab formation in
MEF-5-LO+/+ or MEF-5-LO2/2
To further substantiate the involvement of 5-LO in the
dexamethasone-dependent effect on Ab formation, we next used
MEFs isolated from transgenic mice over-expressing the Swedish
Figure 3. Pharmacological blockade of 5-LO activation prevents dexamethasone-induced Ab formation. N2A-APPswe cells were
incubated with different concentrations of AA-861 (closed bars), and MK-0591 (closed bars), or vehicle (open bars) overnight and then treated with
dexamethasone (10 mM) for 6 h. A–D. Conditioned media collected and Ab1–40 and Ab 1–42 levels assayed (n=3 per condition, **p,0.01; *p,0.05).
Values represent mean 6 SEM. E, F. Representative western blot images of APP and 5-LO protein expression after AA-861 and MK-0591 treatments.
doi:10.1371/journal.pone.0015163.g003
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5-LO (Tg2576/5-LO
2/2) [11], and incubated them with
dexamethasone. As shown in Figure 4A and B, we found that
only cells with the 5-LO available but not the ones lacking the
enzyme responded to dexamethasone with a significant increase in
Ab 1–40 and 1–42 formation, which was associated with a similar
elevation in LTB4 levels (Fig. 4C). Immunoblot analyses did not
show any significant difference in the expression levels of the GR
receptor between the cells with and without the 5-LO gene and in
the presence or absence of dexamethasone (Fig. 4D)
Dexamethasone increases Ab levels in vivo via a 5-LO-
dependent manner
To confirm that the effect of dexamethasone on Ab formation
requires the availability of 5-LO also in vivo, next 5-LO
2/2 and
wild type littermates were administered with dexamethasone for
one week. At the end of the treatment animals were sacrificed and
their brains assayed for endogenous Ab levels. In accordance with
the in vitro effect, we observed that dexamethasone induced a
significant increase in the endogenous levels of Ab in the brains of
WT mice (Fig. 5A, B). However, this effect was abolished in the
brains of mice genetically deficient for 5-LO (Fig. 5A, B).
Dexamethsaone treatment resulted also in a statistically significant
increase in the LTB4 levels in brains form C57Bl6 mice but not 5-
LO2/2 mice (Fig. 5C). Western blot analysis showed that the two
groups of animals had similar expression levels of the GR receptor,
and that these levels were not influenced by the dexamethasone
treatment (Fig. 5D). Furthermore, no significant difference was
observed for steady state levels of APP, BACE-1, ADAM-10
between the two groups of mice and after the dexamethasone
challenge. By contrast, we observed that PS1 levels, one of the
major components of the c-secretase complex, were significantly
elevated in WT mice treated with dexamethasone, but not in 5-
LO2/2 mice (Fig. 5E).
Dexamethasone effect on Ab formation via 5-LO is c-
secretase dependent
Since the in vivo study indicated that dexamethsone increases
Ab formation by influencing the c-secretase pathway, next we
tested the hypothesis that dexamethasone by activating 5-LO
affects Ab formation directly via this pathway. To this end we used
HEK293 cells stably expressing human APP C99, the direct
substrate for c-secretase. Incubation of these cells with dexameth-
asone (10 mM) induced a significant increase in Ab levels (Fig. 6),
which was associated with a significant increase in LTB4
(54.365.8 vs 99.36pg/ml, p,0.05). However, when these cells
were incubated with AA-861, the effect of dexamethasone on Ab
formation was blunted (Fig. 6). On the other hand, under the same
conditions GL189 (EMD Biosciences Inc, La Jolla, CA), a BACE-
1 inhibitor [16], did not induce any change in Ab secretion. By
Figure 4. Effect of dexamethasone on Ab formation in MEF-APP 5-LO+/+ or MEF-APP 5-LO2/2. MEF were incubated with
dexamethasone (10 mM) and conditioned media collected and assayed for (A) Ab1-40 and (B) Ab1-42 levels (n=6 per condition, *p,0.001), and (C)
LTB4 (**p,0.05). D. Representative immunoblots of cell lysates probed with antibodies against glucocorticoid receptor (GR) and b-actin. Values
represent mean 6SEM.
doi:10.1371/journal.pone.0015163.g004
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[17], completely prevented the dexamethasone-dependent effect
on Ab in these cells (Fig. 6).
Discussion
The present paper shows for the first time that the 5-LO
enzymatic pathway is involved in the dexamethasone–dependent
increase of Ab formation in vitro and in vivo. The enzyme 5-LO is
a member of a large family of non-heme iron dioxygenases, whose
main action is to oxidize and convert fatty acids such as
arachidonate to 5-hydroxy-peroxy-eicosatetraenoic (5-HPETE)
and 5-hydroxy-eicosatetraenoic acids (5-HETE), which are then
metabolized into different leukotrienes [18]. This enzyme is widely
expressed in the CNS, where it localizes mainly in neuronal cells.
Its presence has been documented in various brain regions where
significant changes are associated with aging [13,19]. Since aging
is one of the strongest risk factors for developing sporadic AD, it
has been suggested that this pathway may be involved in its
pathogenesis [20]. While the cause of sporadic AD remains
unknown, a combination of environmental and genetic factors has
been implicated in its pathogenesis. Psychosocial stress leading to
altered levels of stress hormones, i.e., glucocorticoids, is considered
one important environmental risk factor that can influence AD age
of onset and/or development [21]. However, the mechanism(s) by
which corticosteroids accelerate the pathogenesis of AD remain to
be fully elucidated [22]. Interestingly, in vitro and in vivo studies
showed that dexamethasone increases the expression levels of 5-
LO [23], suggesting a possible biological link between stress
hormones and the development of AD. With the present paper we
provide the first biological evidence that 5-LO is an essential step
in the dexamethasone-dependent Ab formation. First, we showed
that in neuronal cells dexamethasone increases Ab formation and
activates the 5-LO enzymatic pathway. The requirement of 5-LO
in the dexamethasone-dependent Ab formation was initially
supported by a pharmacological approach. Thus, by using two
distinct pharmacologic tools which block 5-LO activation we
prevented the effect of dexamethasone on Ab. The specific role
and functional importance of 5-LO in this phenomenon was
further corroborated when we used cells genetically deficient for
this enzyme. In this setting, while MEFs with the 5-LO+/+
responded with an elevation in Ab after the dexamethasone
challenge, the same cells but without the 5-LO, i.e., 5-LO
2/2, did
not. Taken together these observations establish the 5-LO as a
Figure 5. Dexamethasone increases Ab levels in vivo. 5-LO knock-out (5-LO2/2) mice and wild type littermates (WT) were treated daily for 7 d
with dexamethasone 5 mg/kg i.p. (n=4) or PBS (n=3). Brain homogenates were assayed for total (A) Ab 1–40 and (B) Ab1-42 levels (open bars: PBS,
closed bars; dexamethasone, *p,0.05). C. LTB4 levels in brain homogenates from mice treated with dexamethasone (closed bars, n=4) or PBS (open
bars, n=3). D. Representative immunoblots of brain homogenates probed with antibodies against APP, 5-LO, BACE-1, ADAM-10, Nicastrin, PS1, APH-
1, Pen-2 and glucocorticoid receptor (GR). E. Quantification of protein blots normalized to b-Actin as a loading control (*p,0.05). Values represent
mean 6 SEM.
doi:10.1371/journal.pone.0015163.g005
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Ab formation. In an effort to elucidate potential mechanisms by
which activation of 5-LO by dexamethasone would ultimately
result in an elevation of Ab levels, we first of all checked whether
there was an effect on total levels of APP, the precursor of the Ab.
Under our experimental conditions no effect on APP was
observed. Next, since dexamethasone biological activity is
regulated by the presence of its own receptor, i.e., GR, we wanted
to assess whether these levels were altered by the pharmacological
tools used. However, no significant change in the protein levels of
this receptor was observed. Importantly we also did not observed
any difference in the GR levels in cells with and without the gene
for the 5-LO, supporting the concept that the lack of effect of the
dexamethasone in the 5-LO
2/2 cells was not secondary to lower
levels or absence of the GR.
In the final part of our studies, we sought to investigate whether
the findings obtained in the in vitro models were reproducible also
in vivo. Thus, when we injected with dexamethasone WT mice we
observed a significant increase in 5-LO activation and Ab
formation, which were completely abolished in mice that were
genetically deficient for the 5-LO. Since previous work indicated
that 5-LO alters Ab formation by modulating the c-secretase
pathway of the APP processing [11], we wanted to see whether this
was also the case in our in vivo experimental setting. To this end,
we observed that while the steady state levels of APP, BACE-1 and
ADAM-10 were unchanged, PS1 protein levels, a major
component of the c-secretase complex, were significantly increased
in the brains of mice receiving dexamethasone, suggesting an
involvement of this secretase. This observation was further
corroborated by another set of experiments, where we used
HEK293 cells that stably express APP-C99, the precursor of Ab
and the immediate substrate for the c-secretase. In these cells,
pharmacological inhibition of 5-LO activation prevented the
dexamethasone-dependent increase of Ab formation to a similar
extent of a classical c-secretase inhibitor. Taken together these
data support the concept that dexamethasone activates the 5-LO
enzymatic pathway, which then affects the APP processing via
modulation of the c-secreatse pathway and ultimately the Ab
levels.
Our findings have particular relevance to AD because it is
established that AD patients display elevated circulating cortisol
levels [24]. Clinical data also suggest that a stressful lifestyle, which
would result in elevated cortisol levels can be a risk factor for AD
onset [25]. In addition, another strong risk factor for AD is the
presence of the apoE4 allele, which has been shown to elevate CSF
cortisol levels [26] more so than the E3 or the E2 allele.
In conclusion, our studies unveil for the first time a novel
functional role for the 5-LO enzymatic pathway in the dexameth-
asone-dependent elevation of Ab, since its pharmacological
inhibition and genetic absence prevent it. Our findings underscore
a novel mechanism by which corticosteroids may affect AD-like
amyloid pathology and suggest that 5-LO could be a therapeutic
target in individuals where stress management or pharmacological
reduction of glucocorticoids approach is not applicable.
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Figure 6. Dexamethasone effect on Ab formation is c-secretase-dependent. HEK-C99 cells were incubated with dexamethasone (10 mM) in
the presence of a 5-LO inhibitor (AA-861 10 mM), a specific b-secretase inhibitor (GL-189, 0.5 mM) or a c-secretase inhibitor (L-685,458, 1 mM), and
conditioned media assayed for Ab1- 40 levels. Values represent mean 6 SEM of 3 experiments (*p,0.05).
doi:10.1371/journal.pone.0015163.g006
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